PDCD1 and non-small cell lung carcinoma: Therefore, combining anti-angiogenic drugs with immunotherapy, which normalizes tumor vasculature through anti-angiogenic drugs and promotes the increase of tumor immune cells (e.g., tumor-infiltrating lymphocytes) in NSCLC, and utilizing immune checkpoint inhibitors which can unlock the functional inhibition of T cells by PD-1 and PD-L1, both act synergistically with each other thus showing better therapeutic effects within solid tumors (151–153).